Cargando…
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1
In non-small cell lung cancer (NSCLC), receptor tyrosine kinases (RTKs) stand out among causal dominant oncogenes, and the ablation of RTK signaling has emerged as a novel tailored therapeutic strategy. Nonetheless, long-term RTK inhibition leads invariably to acquired resistance, tumor recurrence a...
Autores principales: | Voena, C, Di Giacomo, F, Panizza, E, D'Amico, L, Boccalatte, F E, Pellegrino, E, Todaro, M, Recupero, D, Tabbò, F, Ambrogio, C, Martinengo, C, Bonello, L, Pulito, R, Hamm, J, Chiarle, R, Cheng, M, Ruggeri, B, Medico, E, Inghirami, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641361/ https://www.ncbi.nlm.nih.gov/pubmed/23567620 http://dx.doi.org/10.1038/oncsis.2013.7 |
Ejemplares similares
-
Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma
por: Mura, Giulia, et al.
Publicado: (2023) -
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012) -
Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1
por: Voena, Claudia, et al.
Publicado: (2016) -
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities
por: Tabbò, Fabrizio, et al.
Publicado: (2016) -
RHO Family GTPases in the Biology of Lymphoma
por: Voena, Claudia, et al.
Publicado: (2019)